



Working together for our nation's health

Pfizer has a rich heritage of working in the UK. Over the past sixty years, we have discovered and developed medicines which have improved and saved the lives of millions of people across the UK and around the world.

In 2014 we invested more than £178m in R&D in the UK

178,000,000

We are one of the biggest suppliers of medicines to the NHS. We have around 120 different medicines and vaccines which are delivered to pharmacies, surgeries and hospitals across the UK every day

120

Typically, at any one time we have around 80 new medicines or uses (indications) in our R&D pipeline

80

Pfizer has been investing in the UK for more than 60 years

60

Over 2,300 people are employed at our five key UK sites: Walton Oaks, Cambridge, Sandwich, Havant and London


2,300

Around 9 million patients in the UK take a Pfizer medicine every year. That's equivalent to the entire population of London

9

Pfizer is ranked third in terms of the number of UK research collaborations. We contribute to over 232 UK research collaborations, independent research grants and strategic alliances with external partners

232₃



As of 1st January, 2016, Pfizer is conducting 107 ongoing clinical trials...

107

3,656
...which have 3,656 patients randomised

721

...at 721 sites in the UK

3,000

Our colleagues gave almost 3,000 hours of their time to work with a range of community groups

In 2015 we invested over £1,344,000 through donations and a range of support programmes

1,344,000

127,515

We supported patients in need through the donation of 127,515 packs of medicines to developing world countries and global disaster relief efforts

Our scientists invest years of their lives to discover and develop medicines that could one day save yours.

The UK has a world leading science base and is an important place for us to conduct research and development, working in collaboration with scientists, academia, clinicians and other companies. We are committed to investing time, knowledge and money, working alongside the best in UK science to find and develop new medicines and vaccines which prevent illness, improve health and wellbeing and save lives.



Our UK science base reaches across the R&D process from early-stage research to the development and delivery of medicines in oncology, neuroscience and pain, cardiovascular and metabolic disease, vaccines, immunology and inflammation, biosimilars and rare diseases.

Walton Oaks, Surrey is home to our commercial headquarters in the UK. Colleagues here work with UK stakeholders including the NHS, clinicians, regulators, Government and policy makers, and patient groups to support the UK healthcare system and help ensure our medicines reach the clinicians and patients who need them. Colleagues also support our R&D activity across the UK and Europe through clinical trial coordination.

Our **Pfizer Global Supply site, Havant** specialises in packaging and distributing medicines and vaccines across the UK and worldwide. From here, over 73 million doses of large molecule temperature-sensitive vaccines and injectable medicines are packaged and supplied to 86 countries and 122 destinations throughout the world.

Our Device Centre of Excellence at **Cambridge** specialises in the design and development of drug delivery devices such as injectors and inhalers.

The **Genetic Medicine Institute** is a new research facility dedicated to advancing the viability of genetic medicine at pace and scale. We are exploring how we can harness the body's immune system, using it as a natural vehicle to deliver those fixes straight to the faulty gene. We are located in the heart of the UK's science community, sitting alongside our clinical and academic colleagues at Great Ormond Street, Kings College London and University College London – enabling the free flow of knowledge, ideas and best practice.

Our R&D site at **Discovery Park, Sandwich** is one of the largest bio-pharmaceutical science operations in the UK. For more than 60 years our scientists, regulatory professionals and business experts have played a role in the discovery and development of many of Pfizer's most important medicines across a range of therapeutic areas including heart disease, HIV, men's health and pain. Today we are developing medicines for clinical trials in disease areas including cancer, diabetes and Alzheimer's.

"Pfizer has a long and proud history of being part of world class science in the UK, with research activities spanning more than 60 years and amounting to over 232 current collaborations. By working together we increase the chances of discovering and delivering the next medical breakthrough, treatment or cure. We are committed to ensuring UK patients get access to the innovative medicines they need, so they can live a long, healthy and productive life"

Erik Nordkamp, UK Country Manager

No one person has all the answers. Great science means sharing knowledge and working together; through collaboration we can work faster and achieve more.

Pfizer is recognised as the most active collaborator in UK University research, headquartered outside the UK.

Pfizer is delighted to be a partner in the **Dementia Discovery Fund**. This new research initiative aims to boost investment to tackle dementia by bringing together industry, UK government and Alzheimer's Research UK to finance new, early stage drug development projects.



INSPIRE

Our **INSPIRE** sites (Investigator Networks, Site Partnerships and Infrastructure for Research Excellence) in Manchester, Bath, Newcastle, Scotland and NIHR are part of Pfizer's international network of preferred sites for clinical research. These important partnerships enable us to work with the NHS, sharing knowledge and experience, and bring innovative medicines to patients.

Working with more than 26 partners we initiated and established the first **European Bank for induced pluripotent Stem Cells**. This receives and quality checks stem cell lines, and creates and distributes new lines, ensuring European research groups have access to this important technology.

EBiSC

We have around **232 research collaborations**, independent research grants and strategic alliances with scientists, academics and clinicians across the UK.

Developing new medicines for children poses many challenges. Working alongside 13 biopharmaceutical and academic organisations, in a programme funded by Innovate UK, we are working to address these, and hope to accelerate the development of safe and efficacious paediatric medicines. This includes improving their taste to increase adherence in children.

We sponsor **more than 30 PhD programmes** in the UK, ranging from medicinal chemistry, to advanced manufacturing.

CRUK

Pfizer and AstraZeneca are partnering with **Cancer Research UK** to create a pioneering clinical trial for patients with advanced lung cancer. Traditional clinical trials compare one new treatment to the current standard treatment. The 'National Lung Matrix' trial gives researchers unprecedented access to AZ and Pfizer libraries, allowing several treatments to be tested at the same time, within one trial.



We are working with 12 partners across the UK to maximise the potential of computational and predictive science to develop new **digital design** and **manufacturing processes**. Together, we are transforming the way medicines are developed by reducing uncertainty and making better, faster and safer design and operating decisions.

NIHR

Pfizer partners with the **National Institute of Health Research (NIHR) Clinical Research Network (CRN)**, part of our ongoing commitment to develop medical advancements to help cure or control cancer. Collaboration between academia and industry is vital, and this alliance will help bring new trials and treatment options to UK patients.

RDC

The **Rare Diseases Consortium** is a partnership with 15 leading UK universities. Together we identify the most valuable projects and work to develop future medicines for rare diseases. The RDC has recently initiated research into read-through disorders, haematology and neuromuscular disorders.

Beyond our medicines



Pfizer is committed to being an active partner with the NHS in developing solutions to improve the delivery of care and patient outcomes. We believe that by working in partnership - combining skills, experiences and resources - we can tackle some of the challenges facing the NHS today, united by the common goal of putting patients at the heart of our health service.

As well as being a leading supplier of medicines to the NHS, last year we provided more than **£2 million** of grants and more than **£200,000** of colleague time to support programmes designed to improve patient care and/or NHS services.

For example, unused and untaken medicines cost the NHS around **£300 million** each year in England alone. We are working to reduce this cost and improve health by **working with pharmacists** on how to better support patients to take their treatments appropriately and get the most out of their medicines. This work has included local projects and a nationwide campaign to educate patients and encourage them to engage with their pharmacist.

Our work in lung cancer with the Anglia Cancer Network identified savings of up to **£84,000** a year and the potential to shorten the time from diagnosis to starting treatment to 17 days.

Supporting the scientists of tomorrow

Pfizer is also committed to nurturing life science and has a range of long-term and ongoing investments to support the scientists of tomorrow.

We actively support the **National Apprenticeship Programme** across many disciplines including science, engineering, administration, and IT and have over 30 apprentices.

Our UK R&D sites are diverse training grounds for academic placements with students regularly on-site from institutions such as Cambridge University, Manchester University, Imperial College London and King's College London.

Every year, we recruit undergraduate degree students onto our 12 month **Industrial Trainee Placement Scheme**. The scheme provides paid placements across the business, including our commercial business and R&D.

Over **30** of our colleagues are enrolled as **STEMNET ambassadors**, a national programme aimed at inspiring young people in science, technology, engineering and mathematics.

"The apprenticeship scheme at Pfizer has given me an amazing opportunity to gain industry experience in a world class laboratory working with some incredibly talented scientists. It has allowed me to gain my academic qualifications whilst also learning and developing practical skills in an exciting and supportive workplace."

**Charlotte Carr, Apprentice,
Pfizer UK Global Supply**



Working together for our nation's health